MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Net loss-$155,203K (25.39%↑ Y/Y)Income tax benefit(expense)-$15K (-129.41%↓ Y/Y)Other income(expense), net$29,459K (242.22%↑ Y/Y)Interest income$24,885K (16.77%↑ Y/Y)Loss before incometax expense-$155,218K (25.36%↑ Y/Y)Total other income(expense)$54,344K (8972.45%↑ Y/Y)Loss from operations-$209,562K (-0.48%↓ Y/Y)Total operatingexpenses$209,562K (0.48%↑ Y/Y)Gain on sale ofin-process research and...$10,000K Research and development$171,653K (5.44%↑ Y/Y)General andadministrative$47,909K (4.66%↑ Y/Y)
Income Statement
source: myfinsight.com

Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc. (SYRE)